KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control

The utility of KRAS mutations in plasma circulating cell-free DNA (cfDNA) samples as non-invasive biomarkers for the detection of pancreatic cancer has never been evaluated in a large case-control series. We applied a KRAS amplicon-based deep sequencing strategy combined with analytical pipeline spe...

Descripción completa

Detalles Bibliográficos
Autores principales: Le Calvez-Kelm, Florence, Foll, Matthieu, Wozniak, Magdalena B., Delhomme, Tiffany M., Durand, Geoffroy, Chopard, Priscilia, Pertesi, Maroulio, Fabianova, Eleonora, Adamcakova, Zora, Holcatova, Ivana, Foretova, Lenka, Janout, Vladimir, Vallee, Maxime P., Rinaldi, Sabina, Brennan, Paul, McKay, James D., Byrnes, Graham B., Scelo, Ghislaine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346680/
https://www.ncbi.nlm.nih.gov/pubmed/27705932
http://dx.doi.org/10.18632/oncotarget.12386

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346680/
https://www.ncbi.nlm.nih.gov/pubmed/27705932
http://dx.doi.org/10.18632/oncotarget.12386

Ejemplares similares